Novartis (US Rights to Proleukin) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Novartis (US Rights to Proleukin) General Information

Description

Medicinal right to the drug "Proleukin" in the United States. The asset is a synthetic human recombinant interleukin-2 (IL-2) protein which helps to fight against diseases and infections.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Acquirer
Primary Office
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (US Rights to Proleukin) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (US Rights to Proleukin)‘s full profile, request access.

Request a free trial

Novartis (US Rights to Proleukin) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (US Rights to Proleukin)‘s full profile, request access.

Request a free trial